Long-term safety of efgartigimod injections in adults with active idiopathic inflammatory myopathy
Tests efgartigimod given under the skin in adults with active inflammatory muscle disease.
Key facts
- Who runs it
- argenx
- Where
- Seoul, South KoreaSee the siteAlso in 30 other countries, 118 sites
- Trial code
- Registry title
- A Study to Assess the Long-term Safety and Efficacy of a Subcutaneous Formulation of Efgartigimod in Adults With Active Idiopathic Inflammatory Myopathy
- Status
- Enrolling by invitation
- Phase
- Phase 3
- People taking part
- 240 people, planned
- Started
- 12 Sept 2023
- Expected to end
- Sept 2028
- Type of study
- Interventional
- Treatments tested
- Efgartigimod PH20 SC
- Record updated
- 16 October 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with active idiopathic inflammatory myopathy (myositis, a muscle inflammation disease) who completed study ARGX-113-2007. They will get efgartigimod PH20 SC, an injection under the skin, for up to 51 months.
- Age
- 18 years and older
- Sex
- All sexes can join
- Disease stage
- Active idiopathic inflammatory myopathy, including dermatomyositis, polymyositis, immune-mediated necrotizing myopathy and antisynthetase syndrome
- Earlier treatment
- Must have completed trial ARGX-113-2007.
Main reasons for not taking part
- Planning major surgery during the study
- A new health problem since joining ARGX-113-2007 that the study doctor thinks makes joining unsafe or would affect the results
- Known allergic reaction to the study drug or its ingredients
- Any new or returning cancer, except basal cell skin cancer
The registry criteria, word for word
Show all 6 criteriaShow less
Who can take part
- Has completed trial ARGX-113-2007
- Being capable of providing signed informed consent and complying with protocol requirements
- Agrees to use contraceptive measures consistent with local regulations and women of childbearing potential must have a negative urine pregnancy test at baseline before receiving the study drug
Who cannot take part
- Intention to have major surgery during the study period or any other medical condition that has arisen since enrollment in study ARGX-113-2007, that in the investigator's opinion, would confound the results of the study or put the participant at undue risk
- Known hypersensitivity reaction to the study drug or 1 of its excipients
- Development of any malignancy, either new or recurrent, other than basal cell carcinoma of the skin, regardless of relatedness
Where in South Korea
Also in 30 other countries, 118 sites
- Seoul National University HospitalSeoul, South KoreaEnrolling by invitation
About the trial
What the trial wants to find out
The main purpose of this study is to measure the long-term safety and tolerability of efgartigimod PH20 SC in adult participants with Idiopathic Inflammatory Myopathy (IIM) who previously participated in ARGX-113-2007.
Read full original descriptionShow less
The study consists of a treatment period where participants will receive efgartigimod PH20 SC for up to 51 months. The treatment period will be followed by a treatment-free safety follow-up period of 56 days.
The group in the trial
- Efgartigimod PH20 SCTreatment being tested
Participants receiving efgartigimod PH20 subcutaneously
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorSaves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.
Data and sources
- Registry record
- Listed on ClinicalTrials.gov and on the EU's official list of trials (CTIS).How to verify a trial in the registry
- Official title
- A Phase 3, Single-Arm, Multicenter, Open-label Extension of Study ARGX-113-2007 to Investigate the Long-term Safety, Tolerability, and Efficacy of Efgartigimod PH20 SC in Participants Aged 18 Years and Older With Active Idiopathic Inflammatory Myopathy
- Plain-language title
- Long-term safety of efgartigimod injections in adults with active idiopathic inflammatory myopathyGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 14 November 2026.
- Record updated
- 16 October 2026